Developer docs
API playgroundTry for free, no card

Search company profiles

EntroGen

Full company profile

uuid000agdl

Namestring
EntroGen
Legal namestring
EntroGen, Inc.
Websiteurl
entrogen.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

EntroGen, Inc. is a privately held molecular diagnostics company headquartered in Woodland Hills, California, founded in 2007. The company develops and commercializes real-time PCR and next-generation sequencing (NGS) assays for oncology and hematology applications, including companion diagnostics, mutation detection panels, liquid biopsy (ctDNA) assays, microsatellite instability testing, pharmacogenomic genotyping kits, and minimal residual disease (MRD) detection products. Its flagship product, the CRCdx RAS Mutation Detection Kit, received FDA approval in October 2023 as a companion diagnostic for Vectibix (panitumumab) in colorectal cancer and secured CMS national coverage in April 2025, while several other products carry CE-IVD marking for the European market. All products are manufactured under ISO 13485 quality standards and supported by proprietary data analysis software (EPAS and EVA) for result interpretation and LIS/LIMS integration.

The company operates an enterprise go-to-market model combining direct sales with a global network of authorized distributors, targeting clinical diagnostic laboratories, oncology research institutions, and pharmaceutical CDx programs. Revenue is generated primarily through one-time sales of reagent kits priced on a quote basis with net 30 payment terms, alongside instrument sales (BenchBot 4800) and royalty-free software licenses. Strategic clinical collaborations, such as a 2017 partnership with USC Norris Comprehensive Cancer Center for liquid biopsy clinical utility studies, and ongoing CDx development support for pharmaceutical sponsors are part of the commercial mix. Marketing is conducted through industry conferences, scientific webinars, peer-reviewed publications, and direct inquiry funnels rather than mass-market channels.

EntroGen is led by CEO Matthew Minkovsky and Chief Science Officer Dr. Gary Potikyan, with an employee base reported in the 11-50 range. The product line has expanded materially since 2016, with notable launches including the Colorectal Cancer Mutation Detection Panel, BRCA Complete NGS panel, Leukemia Translocation Panel, NGS Targeted Hotspot Panel, ctDNA EGFR and RAS kits, and three new offerings in 2025 (NPM1 One-Step MRD Kit, DPYD Genotyping Kit, and MSI Detection Kit), reflecting a strategy of menu breadth across tumor types and clinical applications.

Short descriptiontext

EntroGen is a privately held molecular diagnostics company based in Woodland Hills, California that develops PCR- and NGS-based oncology assays, including an FDA-approved companion diagnostic, for clinical laboratories, oncology research institutions, and pharmaceutical CDx programs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWoodland Hills, United States
HQ citystring
Woodland Hills
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics, oncology diagnostic kits, companion diagnostics, PCR assay reagents, next-generation sequencing panels
Industry5 codes
PRIMARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAAAM
IVD Reagents, Assay Kits & Consumables (Non-instrument)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Surgical & Medical Instruments & Apparatus3841
Product category
Molecular Diagnostics
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Diagnostic Reagent Kits
TypeOne Time License
Description

EntroGen generates revenue through the sale of molecular diagnostic reagent kits for oncology applications. Products include real-time PCR assays, NGS panels, and companion diagnostics sold as one-time purchases to clinical and research laboratories.

entrogen.com
2Instrument Products
TypeOne Time License
Description

Sale of instruments including the BenchBot 4800 automation system. Instruments come with standard 12-month warranties and optional extended service plans.

entrogen.com
3Software Licenses
TypeLicensing Royalties
Description

Software products including EPAS, EVA, and data analysis tools are licensed to customers. The license is royalty-free, non-exclusive, non-transferable for internal business purposes.

entrogen.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure
Pricing details3 tiers
1CRCdx RAS Mutation Detection Kit - 40 tests per kit
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

FDA-approved companion diagnostic. Specific pricing available upon request through product information form.

entrogen.com
2DPYD Genotyping Kit - 26 tests per kit
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Multiplex real-time PCR assay for research use (RUO). Available directly and through distributors.

entrogen.com
3Colorectal Cancer Mutation Detection Panel - 48 tests per kit
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

RUO in USA, IVD in EU. Available for research use with pricing upon request.

entrogen.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1CRCdx
Description

FDA-approved real-time PCR-based companion diagnostic brand for RAS mutation detection in colorectal cancer

entrogen.com
+4 more records
Core offering1 text field

EntroGen manufactures and sells molecular diagnostic reagent kits (real-time PCR assays and NGS panels) for oncology and hematology applications, along with the Benchbot 4800 automation instrument and EPAS/EVA data analysis software. Products are sold to clinical laboratories, research institutions, and pharmaceutical companies as FDA-approved companion diagnostics, CE-IVD-marked in vitro diagnostics, and research-use-only assays covering mutations in KRAS, NRAS, BRAF, EGFR, PIK3CA, NTRK, DPYD, MSI, BRCA, and other cancer-relevant biomarkers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • CRCdx showed PPA = 99.6%, NPA = 92%, and OPA = 96.2% concordance vs FDA-approved Praxis Extended RAS Panel
+2 more records
Product overview1 text field

EntroGen is a molecular diagnostics company specializing in oncology diagnostics with a portfolio of PCR-based and NGS-based products. The core offering consists of real-time PCR mutation detection kits for various cancer biomarkers (KRAS, NRAS, BRAF, EGFR, PIK3CA, DPYD, MSI, NTRK fusions), automated instruments (Benchbot 4800), companion diagnostics (CRCdx RAS Mutation Detection Kit), and sample preparation/quality control products (pureNA DNA Isolation Kits, IQCA). The product line includes targeted therapies companion tests, liquid biopsy assays (ctDNA), NGS panels (BRCA Complete, RNA Fusion Gene Panel, NGS Targeted Hotspot Panel), and genotyping assays. Products work with established instrument platforms including Illumina sequencers and QuantStudio PCR instruments. The portfolio is completed by proprietary data analysis software (EPAS, EVA) for result interpretation.

Product and service28 records
1CRCdx RAS Mutation Detection Kit
CategoryCompanion Diagnostic (FDA-approved IVD)
Description

FDA-approved real-time PCR-based in vitro diagnostic companion test for detecting 35 KRAS and NRAS somatic mutations in colorectal cancer tissue samples. Helps identify patients who may benefit from Vectibix (panitumumab) anti-EGFR therapy. 40 tests per kit, 2-hour turnaround time. For clinical laboratories performing oncology molecular diagnostics.

2NPM1 One-Step MRD Kit
CategoryPCR Diagnostic Reagent Kit
Description

Highly sensitive assay detecting NPM1 mutations at 0.001% sensitivity level for quantitative minimal residual disease (MRD) assessment in leukemia patients. For clinical and research laboratories.

3DPYD Genotyping Kit
CategoryPharmacogenomic PCR Kit
Description

Multiplex real-time PCR assay for rapid detection of clinically relevant DPYD germline variants associated with reduced dihydropyrimidine dehydrogenase activity and fluoropyrimidine toxicity. Detects 7 AMP Tier 1 variants. 26 tests per kit. For research use (RUO).

4Microsatellite Instability (MSI) Detection Kit
CategoryPCR Diagnostic Reagent Kit
Description

High-resolution melting (HRM) PCR-based assay for fast, reliable MSI detection in colorectal cancer. Detects BAT-25, BAT-26, NR-21, NR-27, and MONO-27 targets. 24 tests per kit. Includes complimentary software for data analysis. For research use (RUO).

5Colorectal Cancer Mutation Detection Panel
CategoryPCR Diagnostic Reagent Kit
Description

PCR-based assay detecting somatic mutations in KRAS, NRAS, BRAF, PIK3CA, and AKT1 genes associated with colorectal cancer. 48 tests per kit, detects 45 mutations across 6 reactions per sample. Validated for FFPE and fresh frozen samples. CE-IVD marking in EU; RUO in USA.

6MLH1 Methylation Detection Kit
CategoryPCR Diagnostic Reagent Kit
Description

Real-time PCR assay using methylation-sensitive restriction enzymes to detect MLH1 promoter methylation in regions C and D. Enables prescreening for Lynch Syndrome and distinguishing sporadic MSI-high tumors. 24 tests per kit, 3-hour turnaround time.

7KRAS Mutation Analysis Kit
CategoryPCR Diagnostic Reagent Kit
Description

Real-time PCR-based assay for detecting somatic KRAS mutations. Below 1% limit of detection. 50 tests per kit, 12 reactions per sample. Detects mutations in codons 12, 13, 61, 117, and 146.

8KRAS/BRAF Mutation Analysis Kit
CategoryPCR Diagnostic Reagent Kit
Description

Rapid real-time PCR assay detecting KRAS and BRAF mutations to identify mCRC patients unlikely to benefit from EGFR-targeted therapy. 50 tests per kit, 13 reactions per sample.

9NTRK Fusion Gene Detection Kit
CategoryPCR Diagnostic Reagent Kit
Description

Real-time qPCR assay detecting 65 NTRK1, NTRK2, and NTRK3 gene fusion variants from FFPE RNA samples. Used for cancer diagnosis and targeted therapy selection for Trk inhibitor treatments. 48 tests per kit, 8 reactions per sample.

10RNA Fusion Gene Panel for Illumina
CategoryNGS Reagent Kit
Description

Multiplexed next-generation sequencing assay detecting 305 fusion genes across 23 cancer-associated genes. Includes reagents for reverse transcription, target enrichment, and library preparation. Compatible with Illumina NextSeq 500, MiniSeq, and MiSeq. Average amplicon size 145 bp.

11PIK3CA Mutation Analysis Kit
CategoryPCR Diagnostic Reagent Kit
Description

Real-time PCR assay detecting 11 somatic PIK3CA mutations in HR-positive HER2-negative breast cancer and KRAS wild-type metastatic colorectal cancer. 48 tests per kit, 6 reactions per sample. 2-hour turnaround.

12ctDNA RAS Mutation Detection Kit
CategoryLiquid Biopsy PCR Kit
Description

Plasma-based assay for detecting KRAS and NRAS mutations in circulating tumor DNA. Liquid biopsy test for when tumor tissue is limited. 40 tests per kit, 2 reactions per sample.

13ctDNA EGFR Mutation Detection Kit
CategoryLiquid Biopsy PCR Kit
Description

Ultra-sensitive real-time PCR assay for detecting EGFR mutations from circulating tumor DNA in plasma. Detects mutations in exons 18, 19, 20, and 21. 48 tests per kit, 7 reactions per sample.

14EGFR Mutation Analysis Kit
CategoryPCR Diagnostic Reagent Kit
Description

Highly sensitive real-time PCR assay detecting key EGFR mutations in exons 18-21 for guiding targeted cancer therapy decisions. 52 tests per kit. Includes complementary EPAS analysis software.

15EGFRX Mutation Analysis Extension Kit
CategoryPCR Diagnostic Reagent Kit
Description

Real-time PCR add-on assay expanding EGFR-RT52 kit coverage for rare EGFR mutations in codons L858, L861, and E709. 1% limit of detection. 52 tests per kit, 3 reactions per sample.

16Lung Cancer RNA Panel
CategoryPCR Diagnostic Reagent Kit
Description

One-step RT-qPCR assay for detecting ALK, ROS1, and RET fusion genes and MET exon 14 skipping mutations in non-small cell lung cancer. 48 tests per kit. Optimized for FFPE, fresh-frozen, and tumor biopsies.

17BRAF Codon 600 Mutation Analysis Kit II
CategoryPCR Diagnostic Reagent Kit
Description

Real-time PCR assay detecting BRAF exon 15 somatic mutations. Detects as low as 1% mutant allelic frequency. 64 tests per kit, 5 reactions per sample. Works with FFPE, fresh frozen, FNA, and plasma samples.

18c-Kit Mutation Detection Kit
CategoryPCR Diagnostic Reagent Kit
Description

Real-time PCR assay detecting somatic c-KIT mutations in GIST, melanoma, and mastocytosis. Below 5% limit of detection. 44 tests per kit. Detects 21 mutations including EX11, EX17, EX13, EX9 variants.

19BRCA Complete NGS Panel
CategoryNGS Reagent Kit
Description

Targeted NGS panel for BRCA1 and BRCA2 exome sequencing. Compatible with blood, fresh frozen, and FFPE samples. 2% limit of detection, 95% uniformity. Validated for Illumina MiniSeq, MiSeq, and NextSeq platforms. CE-IVD marked.

20NGS Targeted Hotspot Panel
CategoryNGS Reagent Kit
Description

NGS assay detecting somatic mutations and copy number variations across 16 cancer genes including BRAF, EGFR, KRAS, NRAS, PIK3CA, TP53. 200 amplicons, average 164 bp. Compatible with FFPE, fresh frozen, blood, and cell lines. Validated for Illumina platforms.

21UGT1A1 Genotyping Kit
CategoryPharmacogenomic PCR Kit
Description

Real-time PCR assay for differentiation of UGT1A1*1 and *28 polymorphisms in human genomic DNA. Detects promoter polymorphisms for pharmacogenomics applications including irinotecan toxicity assessment. 50 tests per kit.

22Leukemia Translocation Panel
CategoryPCR Diagnostic Reagent Kit
Description

Multiplexed one-step RT-PCR assay detecting eleven variants in 6 common leukemia-associated translocations (AML1-ETO, CBFB-MYH11, MLL-AF4, TEL-AML1, E2A-PBX1, PML-RARA). Results in 90 minutes. CE-IVD marked.

23Benchbot 4800
CategoryAutomation Instrument
Description

Automated sample processing instrument for molecular diagnostics workflows. Streamlines the process from sample to PCR plate in four simple steps. Standard 12-month warranty with optional extended service plans.

24pureNA Genomic DNA Isolation Kit
CategorySample Preparation Kit
Description

Magnetic bead-based genomic DNA extraction kit for FFPE tissue samples. High-purity DNA suitable for qPCR and NGS applications. 50 extractions per kit.

25pureNA Cell-Free DNA Isolation Kit
CategorySample Preparation Kit
Description

Cell-free DNA extraction kit from fresh or frozen plasma. High specificity for cfDNA versus genomic DNA. Processes samples in under 1 hour, recovering cfDNA from as little as 2ml plasma.

26Library Quantification for Illumina
CategoryNGS Accessory Kit
Description

qPCR-based kit for accurate quantification of Illumina sequencing libraries. Selectively amplifies adapter-ligated DNA fragments. Includes pre-diluted standards, primer mixes, and 2X master mix. 75 triplicate reactions.

27EPAS Software (EntroGen PCR Analysis Software)
CategoryAnalysis Software
Description

Proprietary data analysis software for streamlined PCR/qPCR result interpretation and reporting. Generates easy-to-interpret reports exportable for integration with laboratory information management systems (LIS/LIMS). Bundled with EntroGen reagent kits including CRCdx and EGFR Mutation Analysis Kit.

28EVA Software (EntroGen Variant Analysis Software)
CategoryAnalysis Software
Description

Proprietary bioinformatics software for NGS data interpretation. Reports fusion gene identities and genomic breakpoint positions. Used with RNA Fusion Gene Panel and NGS Targeted Hotspot Panel. Available for local installation.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-06-12
Description

Clinical collaboration to conduct an observational study determining the clinical utility of EntroGen's liquid biopsy solutions for lung cancer patients. The year-long study assesses and monitors EGFR activating and resistance mutations in blood of NSCLC patients undergoing EGFR TKI therapy. Dr. Jorge Nieva serves as principle investigator.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Qiagen offers the therascreen line of FDA-approved companion diagnostics (KRAS, EGFR, etc.) and a broad real-time PCR and NGS oncology portfolio. It is the most directly comparable commercial peer to EntroGen in the molecular diagnostics kit business.

TypeDirect peer
Description

Asuragen, now part of Bio-Techne, sells molecular diagnostic kits for oncology including KRAS, BRAF, and other mutation detection assays. Directly comparable product profile (PCR-based oncology kits, CLIA-validated workflows) to EntroGen.

TypeBroad incumbent
Description

Illumina provides the NGS platforms (MiSeq, MiniSeq, NextSeq) on which EntroGen's BRCA Complete, RNA Fusion Gene Panel, and NGS Targeted Hotspot Panel run. Broad incumbent enabling the NGS-based portion of EntroGen's portfolio while also offering competing oncology NGS content.

TypeDirect peer
Description

Amoy Diagnostics is a China-headquartered molecular diagnostics company specializing in PCR-based companion diagnostics for oncology (EGFR, KRAS, ALK, ROS1). Comparable product overlap and clinical oncology focus, though primarily serving the Asian market.

TypeBroad incumbent
Description

Roche offers the cobas line of FDA-approved KRAS, EGFR, BRAF, and other oncology companion diagnostics. Broad incumbent dominating the IVD oncology market with vertically integrated instrument-reagent-software workflows.

TypeDirect peer
Description

Bio-Rad offers QXDx and ddPCR-based molecular diagnostic kits for oncology and hematology applications, including KRAS and other mutation detection assays. Comparable as a specialty molecular diagnostics kit provider targeting clinical and research labs.

TypeRegional player
Description

NeoGenomics is a US-focused oncology clinical laboratory offering molecular testing services (KRAS, EGFR, NGS panels) to oncologists and biopharma. Adjacent comparable in oncology molecular diagnostics but operates as a service lab rather than a kit manufacturer.

TypeEmerging player
Description

Sysmex provides hematology and molecular diagnostics products, including leukemia and MRD-related assays. Comparable as a specialty diagnostics provider with overlap in EntroGen's Leukemia Translocation Panel and NPM1 MRD Kit categories.

TypeEmerging player
Description

HTG Molecular Diagnostics offers molecular profiling assays for oncology using proprietary technology. Comparable as a small-cap molecular diagnostics company pursuing oncology biomarker and companion diagnostic applications.

TypeBroad incumbent
Description

Thermo Fisher (Applied Biosystems) supplies the QuantStudio real-time PCR platform, TaqMan mutation detection assays, and Oncomine NGS panels used across oncology molecular diagnostics. Broad incumbent that both enables (instrument platform) and competes with EntroGen.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EntroGen

Molecular Diagnosticsentrogen.com

EntroGen is a privately held molecular diagnostics company based in Woodland Hills, California that develops PCR- and NGS-based oncology assays, including an FDA-approved companion diagnostic, for clinical laboratories, oncology research institutions, and pharmaceutical CDx programs.

What EntroGen does

EntroGen, Inc. is a privately held molecular diagnostics company headquartered in Woodland Hills, California, founded in 2007. The company develops and commercializes real-time PCR and next-generation sequencing (NGS) assays for oncology and hematology applications, including companion diagnostics, mutation detection panels, liquid biopsy (ctDNA) assays, microsatellite instability testing, pharmacogenomic genotyping kits, and minimal residual disease (MRD) detection products. Its flagship product, the CRCdx RAS Mutation Detection Kit, received FDA approval in October 2023 as a companion diagnostic for Vectibix (panitumumab) in colorectal cancer and secured CMS national coverage in April 2025, while several other products carry CE-IVD marking for the European market. All products are manufactured under ISO 13485 quality standards and supported by proprietary data analysis software (EPAS and EVA) for result interpretation and LIS/LIMS integration.

The company operates an enterprise go-to-market model combining direct sales with a global network of authorized distributors, targeting clinical diagnostic laboratories, oncology research institutions, and pharmaceutical CDx programs. Revenue is generated primarily through one-time sales of reagent kits priced on a quote basis with net 30 payment terms, alongside instrument sales (BenchBot 4800) and royalty-free software licenses. Strategic clinical collaborations, such as a 2017 partnership with USC Norris Comprehensive Cancer Center for liquid biopsy clinical utility studies, and ongoing CDx development support for pharmaceutical sponsors are part of the commercial mix. Marketing is conducted through industry conferences, scientific webinars, peer-reviewed publications, and direct inquiry funnels rather than mass-market channels.

EntroGen is led by CEO Matthew Minkovsky and Chief Science Officer Dr. Gary Potikyan, with an employee base reported in the 11-50 range. The product line has expanded materially since 2016, with notable launches including the Colorectal Cancer Mutation Detection Panel, BRCA Complete NGS panel, Leukemia Translocation Panel, NGS Targeted Hotspot Panel, ctDNA EGFR and RAS kits, and three new offerings in 2025 (NPM1 One-Step MRD Kit, DPYD Genotyping Kit, and MSI Detection Kit), reflecting a strategy of menu breadth across tumor types and clinical applications.

EntroGen firmographics

Firmographics
Name
EntroGen
Legal name
EntroGen, Inc.
Website
https://entrogen.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
EntroGen is a privately held molecular diagnostics company based in Woodland Hills, California that develops PCR- and NGS-based oncology assays, including an FDA-approved companion diagnostic, for clinical laboratories, oncology research institutions, and pharmaceutical CDx programs.
Ownership category
akta.pro rank

EntroGen industry classification

Industry
Product category
Molecular Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAAAM
IVD Reagents, Assay Kits & Consumables (Non-instrument)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Molecular diagnostics
  • Oncology diagnostic kits
  • Companion diagnostics
  • PCR assay reagents
  • Next-generation sequencing panels

Where EntroGen is headquartered

Location

Headquarters

HQ city
Woodland Hills
HQ country
United States
HQ region
North America

Offices1 record

Markets served

EntroGen business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

  1. Diagnostic Reagent Kits: EntroGen generates revenue through the sale of molecular diagnostic reagent kits for oncology applications. Products include real-time PCR assays, NGS panels, and companion diagnostics sold as one-time purchases to clinical and research laboratories.
  2. Instrument Products: Sale of instruments including the BenchBot 4800 automation system. Instruments come with standard 12-month warranties and optional extended service plans.
  3. Software Licenses: Software products including EPAS, EVA, and data analysis tools are licensed to customers. The license is royalty-free, non-exclusive, non-transferable for internal business purposes.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goCRCdx RAS Mutation Detection Kit - 40 tests per kit
One time/ perpetual licensePay-as-you-goDPYD Genotyping Kit - 26 tests per kit
One time/ perpetual licensePay-as-you-goColorectal Cancer Mutation Detection Panel - 48 tests per kit

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

EntroGen product offering

Product offering

Core offering

EntroGen manufactures and sells molecular diagnostic reagent kits (real-time PCR assays and NGS panels) for oncology and hematology applications, along with the Benchbot 4800 automation instrument and EPAS/EVA data analysis software. Products are sold to clinical laboratories, research institutions, and pharmaceutical companies as FDA-approved companion diagnostics, CE-IVD-marked in vitro diagnostics, and research-use-only assays covering mutations in KRAS, NRAS, BRAF, EGFR, PIK3CA, NTRK, DPYD, MSI, BRCA, and other cancer-relevant biomarkers.

Product overview

EntroGen is a molecular diagnostics company specializing in oncology diagnostics with a portfolio of PCR-based and NGS-based products. The core offering consists of real-time PCR mutation detection kits for various cancer biomarkers (KRAS, NRAS, BRAF, EGFR, PIK3CA, DPYD, MSI, NTRK fusions), automated instruments (Benchbot 4800), companion diagnostics (CRCdx RAS Mutation Detection Kit), and sample preparation/quality control products (pureNA DNA Isolation Kits, IQCA). The product line includes targeted therapies companion tests, liquid biopsy assays (ctDNA), NGS panels (BRCA Complete, RNA Fusion Gene Panel, NGS Targeted Hotspot Panel), and genotyping assays. Products work with established instrument platforms including Illumina sequencers and QuantStudio PCR instruments. The portfolio is completed by proprietary data analysis software (EPAS, EVA) for result interpretation.

Differentiator

Problem solved

Functional benefit

Brands

  • CRCdx: FDA-approved real-time PCR-based companion diagnostic brand for RAS mutation detection in colorectal cancer
  • DPYD Genotyping Kit
  • MSI Detection Kit
  • Benchbot 4800
  • EPAS

Products and services

  • CRCdx RAS Mutation Detection Kit FDA-approved real-time PCR-based in vitro diagnostic companion test for detecting 35 KRAS and NRAS somatic mutations in colorectal cancer tissue samples. Helps identify patients who may benefit from Vectibix (panitumumab) anti-EGFR therapy. 40 tests per kit, 2-hour turnaround time. For clinical laboratories performing oncology molecular diagnostics.
  • NPM1 One-Step MRD Kit Highly sensitive assay detecting NPM1 mutations at 0.001% sensitivity level for quantitative minimal residual disease (MRD) assessment in leukemia patients. For clinical and research laboratories.
  • DPYD Genotyping Kit Multiplex real-time PCR assay for rapid detection of clinically relevant DPYD germline variants associated with reduced dihydropyrimidine dehydrogenase activity and fluoropyrimidine toxicity. Detects 7 AMP Tier 1 variants. 26 tests per kit. For research use (RUO).
  • Microsatellite Instability (MSI) Detection Kit High-resolution melting (HRM) PCR-based assay for fast, reliable MSI detection in colorectal cancer. Detects BAT-25, BAT-26, NR-21, NR-27, and MONO-27 targets. 24 tests per kit. Includes complimentary software for data analysis. For research use (RUO).
  • Colorectal Cancer Mutation Detection Panel PCR-based assay detecting somatic mutations in KRAS, NRAS, BRAF, PIK3CA, and AKT1 genes associated with colorectal cancer. 48 tests per kit, detects 45 mutations across 6 reactions per sample. Validated for FFPE and fresh frozen samples. CE-IVD marking in EU; RUO in USA.
  • MLH1 Methylation Detection Kit Real-time PCR assay using methylation-sensitive restriction enzymes to detect MLH1 promoter methylation in regions C and D. Enables prescreening for Lynch Syndrome and distinguishing sporadic MSI-high tumors. 24 tests per kit, 3-hour turnaround time.
  • KRAS Mutation Analysis Kit Real-time PCR-based assay for detecting somatic KRAS mutations. Below 1% limit of detection. 50 tests per kit, 12 reactions per sample. Detects mutations in codons 12, 13, 61, 117, and 146.
  • KRAS/BRAF Mutation Analysis Kit Rapid real-time PCR assay detecting KRAS and BRAF mutations to identify mCRC patients unlikely to benefit from EGFR-targeted therapy. 50 tests per kit, 13 reactions per sample.
  • NTRK Fusion Gene Detection Kit Real-time qPCR assay detecting 65 NTRK1, NTRK2, and NTRK3 gene fusion variants from FFPE RNA samples. Used for cancer diagnosis and targeted therapy selection for Trk inhibitor treatments. 48 tests per kit, 8 reactions per sample.
  • RNA Fusion Gene Panel for Illumina Multiplexed next-generation sequencing assay detecting 305 fusion genes across 23 cancer-associated genes. Includes reagents for reverse transcription, target enrichment, and library preparation. Compatible with Illumina NextSeq 500, MiniSeq, and MiSeq. Average amplicon size 145 bp.
  • PIK3CA Mutation Analysis Kit Real-time PCR assay detecting 11 somatic PIK3CA mutations in HR-positive HER2-negative breast cancer and KRAS wild-type metastatic colorectal cancer. 48 tests per kit, 6 reactions per sample. 2-hour turnaround.
  • ctDNA RAS Mutation Detection Kit Plasma-based assay for detecting KRAS and NRAS mutations in circulating tumor DNA. Liquid biopsy test for when tumor tissue is limited. 40 tests per kit, 2 reactions per sample.
  • ctDNA EGFR Mutation Detection Kit Ultra-sensitive real-time PCR assay for detecting EGFR mutations from circulating tumor DNA in plasma. Detects mutations in exons 18, 19, 20, and 21. 48 tests per kit, 7 reactions per sample.
  • EGFR Mutation Analysis Kit Highly sensitive real-time PCR assay detecting key EGFR mutations in exons 18-21 for guiding targeted cancer therapy decisions. 52 tests per kit. Includes complementary EPAS analysis software.
  • EGFRX Mutation Analysis Extension Kit Real-time PCR add-on assay expanding EGFR-RT52 kit coverage for rare EGFR mutations in codons L858, L861, and E709. 1% limit of detection. 52 tests per kit, 3 reactions per sample.
  • Lung Cancer RNA Panel One-step RT-qPCR assay for detecting ALK, ROS1, and RET fusion genes and MET exon 14 skipping mutations in non-small cell lung cancer. 48 tests per kit. Optimized for FFPE, fresh-frozen, and tumor biopsies.
  • BRAF Codon 600 Mutation Analysis Kit II Real-time PCR assay detecting BRAF exon 15 somatic mutations. Detects as low as 1% mutant allelic frequency. 64 tests per kit, 5 reactions per sample. Works with FFPE, fresh frozen, FNA, and plasma samples.
  • c-Kit Mutation Detection Kit Real-time PCR assay detecting somatic c-KIT mutations in GIST, melanoma, and mastocytosis. Below 5% limit of detection. 44 tests per kit. Detects 21 mutations including EX11, EX17, EX13, EX9 variants.
  • BRCA Complete NGS Panel Targeted NGS panel for BRCA1 and BRCA2 exome sequencing. Compatible with blood, fresh frozen, and FFPE samples. 2% limit of detection, 95% uniformity. Validated for Illumina MiniSeq, MiSeq, and NextSeq platforms. CE-IVD marked.
  • NGS Targeted Hotspot Panel NGS assay detecting somatic mutations and copy number variations across 16 cancer genes including BRAF, EGFR, KRAS, NRAS, PIK3CA, TP53. 200 amplicons, average 164 bp. Compatible with FFPE, fresh frozen, blood, and cell lines. Validated for Illumina platforms.
  • UGT1A1 Genotyping Kit Real-time PCR assay for differentiation of UGT1A1*1 and *28 polymorphisms in human genomic DNA. Detects promoter polymorphisms for pharmacogenomics applications including irinotecan toxicity assessment. 50 tests per kit.
  • Leukemia Translocation Panel Multiplexed one-step RT-PCR assay detecting eleven variants in 6 common leukemia-associated translocations (AML1-ETO, CBFB-MYH11, MLL-AF4, TEL-AML1, E2A-PBX1, PML-RARA). Results in 90 minutes. CE-IVD marked.
  • Benchbot 4800 Automated sample processing instrument for molecular diagnostics workflows. Streamlines the process from sample to PCR plate in four simple steps. Standard 12-month warranty with optional extended service plans.
  • pureNA Genomic DNA Isolation Kit Magnetic bead-based genomic DNA extraction kit for FFPE tissue samples. High-purity DNA suitable for qPCR and NGS applications. 50 extractions per kit.
  • pureNA Cell-Free DNA Isolation Kit Cell-free DNA extraction kit from fresh or frozen plasma. High specificity for cfDNA versus genomic DNA. Processes samples in under 1 hour, recovering cfDNA from as little as 2ml plasma.
  • Library Quantification for Illumina qPCR-based kit for accurate quantification of Illumina sequencing libraries. Selectively amplifies adapter-ligated DNA fragments. Includes pre-diluted standards, primer mixes, and 2X master mix. 75 triplicate reactions.
  • EPAS Software (EntroGen PCR Analysis Software) Proprietary data analysis software for streamlined PCR/qPCR result interpretation and reporting. Generates easy-to-interpret reports exportable for integration with laboratory information management systems (LIS/LIMS). Bundled with EntroGen reagent kits including CRCdx and EGFR Mutation Analysis Kit.
  • EVA Software (EntroGen Variant Analysis Software) Proprietary bioinformatics software for NGS data interpretation. Reports fusion gene identities and genomic breakpoint positions. Used with RNA Fusion Gene Panel and NGS Targeted Hotspot Panel. Available for local installation.

Quantifiable outcome

  • CRCdx showed PPA = 99.6%, NPA = 92%, and OPA = 96.2% concordance vs FDA-approved Praxis Extended RAS Panel
  • +2 more outcomes

Companies that use EntroGen

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

EntroGen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

Feature6 records

EntroGen partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • University of Southern California Norris Comprehensive Cancer CentercoreStrategic or Co-development Partner · 12 June 2017Clinical collaboration to conduct an observational study determining the clinical utility of EntroGen's liquid biopsy solutions for lung cancer patients. The year-long study assesses and monitors EGFR activating and resistance mutations in blood of NSCLC patients undergoing EGFR TKI therapy. Dr. Jorge Nieva serves as principle investigator.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

EntroGen competitors and assessment

Company assessment

Direct peers

  • Qiagen: Qiagen offers the therascreen line of FDA-approved companion diagnostics (KRAS, EGFR, etc.) and a broad real-time PCR and NGS oncology portfolio. It is the most directly comparable commercial peer to EntroGen in the molecular diagnostics kit business.
  • Asuragen (Bio-Techne): Asuragen, now part of Bio-Techne, sells molecular diagnostic kits for oncology including KRAS, BRAF, and other mutation detection assays. Directly comparable product profile (PCR-based oncology kits, CLIA-validated workflows) to EntroGen.
  • Amoy Diagnostics: Amoy Diagnostics is a China-headquartered molecular diagnostics company specializing in PCR-based companion diagnostics for oncology (EGFR, KRAS, ALK, ROS1). Comparable product overlap and clinical oncology focus, though primarily serving the Asian market.
  • Bio-Rad Laboratories: Bio-Rad offers QXDx and ddPCR-based molecular diagnostic kits for oncology and hematology applications, including KRAS and other mutation detection assays. Comparable as a specialty molecular diagnostics kit provider targeting clinical and research labs.

Broad incumbents

  • Illumina: Illumina provides the NGS platforms (MiSeq, MiniSeq, NextSeq) on which EntroGen's BRCA Complete, RNA Fusion Gene Panel, and NGS Targeted Hotspot Panel run. Broad incumbent enabling the NGS-based portion of EntroGen's portfolio while also offering competing oncology NGS content.
  • Roche Diagnostics: Roche offers the cobas line of FDA-approved KRAS, EGFR, BRAF, and other oncology companion diagnostics. Broad incumbent dominating the IVD oncology market with vertically integrated instrument-reagent-software workflows.
  • Thermo Fisher Scientific: Thermo Fisher (Applied Biosystems) supplies the QuantStudio real-time PCR platform, TaqMan mutation detection assays, and Oncomine NGS panels used across oncology molecular diagnostics. Broad incumbent that both enables (instrument platform) and competes with EntroGen.

Regional players

  • NeoGenomics: NeoGenomics is a US-focused oncology clinical laboratory offering molecular testing services (KRAS, EGFR, NGS panels) to oncologists and biopharma. Adjacent comparable in oncology molecular diagnostics but operates as a service lab rather than a kit manufacturer.

Emerging players

  • Sysmex: Sysmex provides hematology and molecular diagnostics products, including leukemia and MRD-related assays. Comparable as a specialty diagnostics provider with overlap in EntroGen's Leukemia Translocation Panel and NPM1 MRD Kit categories.
  • HTG Molecular Diagnostics: HTG Molecular Diagnostics offers molecular profiling assays for oncology using proprietary technology. Comparable as a small-cap molecular diagnostics company pursuing oncology biomarker and companion diagnostic applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

EntroGen social profiles

Digital presence

EntroGen compliance and trust

Trust signal

Compliance1 record

EntroGen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EntroGen leadership team

Management profile

Number of profiles

Profiles2 records

EntroGen funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EntroGen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EntroGen

What does EntroGen do?

EntroGen manufactures and sells molecular diagnostic reagent kits (real-time PCR assays and NGS panels) for oncology and hematology applications, along with the Benchbot 4800 automation instrument and EPAS/EVA data analysis software. Products are sold to clinical laboratories, research institutions, and pharmaceutical companies as FDA-approved companion diagnostics, CE-IVD-marked in vitro diagnostics, and research-use-only assays covering mutations in KRAS, NRAS, BRAF, EGFR, PIK3CA, NTRK, DPYD, MSI, BRCA, and other cancer-relevant biomarkers.

Is EntroGen a public or private company?

EntroGen is a private company. It is classified as unknown and is currently operating.

When was EntroGen founded?

EntroGen was founded in 2007. It employs 11 to 50 people.

Where is EntroGen based?

EntroGen is headquartered in Woodland Hills, United States, in the North America region.

How does EntroGen make money?

Three revenue lines are on record. Diagnostic Reagent Kits are the primary driver. The others are instrument Products and software Licenses.

Who are EntroGen's main competitors?

Direct peers on record are Qiagen, Asuragen (Bio-Techne), Amoy Diagnostics and Bio-Rad Laboratories. Broad incumbents are Illumina, Roche Diagnostics and Thermo Fisher Scientific. NeoGenomics is listed as a regional player. Emerging players are Sysmex and HTG Molecular Diagnostics.

Does EntroGen have an API?

No public API is recorded for EntroGen.

What industry is EntroGen in?

EntroGen's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays), with a secondary code of HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales